Trial Information - Phase III
A Phase III randomized study to assess the efficacy and safety of alpelisib(BYL719) in combination with olaparib in patients with BRCA wild-type, platinum-resistant or refractory high grade serous ovarian cancer.
Protocol ID: CBYL719K12301
Sponsor: Novartis Pharmaceuticals Corporation
Status: OPEN TO ENROLLMENT
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
